http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/164 Wed, 08 Apr 2026 03:51:44 GMT 2026-04-08T03:51:44Z http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/421 Title: Pathogenesis and clinical implications of HIV-related anemia in 2013 Authors: Redig, Amanda J.; Berliner, Nancy Abstract: Anemia is a common feature of HIV-related disease and has been uniformly demonstrated to be an independent predictor of morbidity and mortality. Although anemia often responds to combination antiretroviral therapy, many patients remain anemic despite therapy and such persistent anemia continues to negatively affect prognosis regardless of drug response. Anemia is also a common feature of normal aging. We postulate that the pathophysiology of anemia in HIV, especially that which persists in the face of combination antiretroviral therapy, is a reflection of underlying proinflammatory pathways that are also thought to contribute to anemia in the elderly, as well as other age-related chronic diseases such as cardiovascular disease and chronic obstructive pulmonary disease. This suggests that HIV induces inflammatory pathways that are associated with a pattern of accelerated aging and that anemia is a biomarker of these processes. A better understanding of the pathophysiology of HIV-related anemia may provide important entry points for improving the chronic manifestations of HIV-related disease. Article Tue, 01 Jan 2013 00:00:00 GMT https://ikr.inceif.org/retrieve/56b802c0-8f7d-44fc-9e5f-0303fb979ee6/Hematology-2013-Redig-377-81.pdf.jpg 2013-01-01T00:00:00Z http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/417 Title: Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights Authors: Platzbecker, Uwe Abstract: Recently, a refined cytogenetic and molecular classification fundamentally changed the prognostication of patients with myelodysplastic syndromes (MDS). The increasingly complex heterogeneity of this disease entity is mirrored by life expectancy rates ranging from almost a decade for very low-risk disease down to several months in higher-risk patients, even with conventional treatments. Intensive treatment approaches are hampered by the older age of most of the patients, potentially leading to an unacceptable adverse event rate. This is especially true for allogeneic hematopoietic stem cell transplantation (HCT), which, albeit of curative intent, can lead to considerable morbidity and mortality mostly as a result of organ toxicity, infectious complications, and GVHD. Furthermore, innovative drug developments, including hypomethylating agents, have broadened the therapeutic armamentarium and, although not curative, can lead to durable responses in subgroups of patients with higher-risk MDS. In fact, there is still no prospective randomized trial available that formally demonstrates the benefit of allogeneic HCT compared with standard treatments in MDS patients. In the absence of randomized data, when considering allogeneic HCT, emphasis should be put on patient selection and optimization of the pre- and posttransplantation treatment period. In these patients, a thorough comorbidity evaluation is mandatory and stratification according to age, cytogenetics, cytopenias, disease-related quality of life, and available alternative treatments should be performed in deciding whether, when, and how to perform allogeneic HCT. Article Tue, 01 Jan 2013 00:00:00 GMT https://ikr.inceif.org/retrieve/c79489ce-0392-4d0d-b780-e10a29a119d2/Hematology-2013-Platzbecker-522-8.pdf.jpg 2013-01-01T00:00:00Z http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/416 Title: Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Authors: Paschka, Peter; Dohner, Konstanze Abstract: Acute myeloid leukemia (AML) with t(8;21) or inv(16) is commonly referred to as core-binding factor AML (CBF-AML). The incorporation of high-dose cytarabine for postremission therapy has substantially improved the outcome of CBF-AML patients, especially when administered in the setting of repetitive cycles. For many years, high-dose cytarabine was the standard treatment in CBF-AML resulting in favorable long-term outcome in approximately half of the patients. Therefore, CBF-AML patients are generally considered to be a favorable AML group. However, a substantial proportion of patients cannot be cured by the current treatment. Additional genetic alterations discovered in CBF-AML help in our understanding of the process of leukemogenesis and some of them may refine the risk assessment in CBF-AML and, importantly, also serve as targets for novel therapeutic approaches. We discuss the clinical and genetic heterogeneity of CBF-AML, with a particular focus on the role of KIT mutations as a prognosticator, and also discuss recent efforts to target the KIT kinase in the context of existing therapeutic regimens. Article Tue, 01 Jan 2013 00:00:00 GMT https://ikr.inceif.org/retrieve/2e6f47d8-184c-4455-83cb-a855d2f5dcab/Hematology-2013-Paschka-209-19.pdf.jpg 2013-01-01T00:00:00Z http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/415 Title: UnderstandingMYC-driven aggressive B-cell lymphomas: pathogenesis and classification Authors: Ott, German; Rosenwald, Andreas; Campo3, Elias Abstract: MYC is a potent oncogene initially identified as the target of the t(8;14)(q24;q32) chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified in other mature B-cell neoplasms that are usually associated with an aggressive clinical behavior. Most of these tumors originate in cells that do not normally express MYC protein. The oncogenic events leading to MYC up-regulation seem to overcome the inhibitory effect of physiological repressors such as BCL6 or BLIMP1. Aggressive lymphomas frequently carry additional oncogenic alterations that cooperate with MYC dysregulation, likely counteracting its proapoptotic function. The development of FISH probes and new reliable antibodies have facilitated the study of MYC gene alterations and protein expression in large series of patients, providing new clinical and biological perspectives regarding MYC dysregulation in aggressive lymphomas. MYC gene alterations in large B-cell lymphomas are frequently associated with BCL2 or BCL6 translocations conferring a very aggressive behavior. Conversely, MYC protein up-regulation may occur in tumors without apparent gene alterations, and its association with BCL2 overexpression also confers a poor prognosis. In this review, we integrate all of this new information and discuss perspectives, challenges, and open questions for the diagnosis and management of patients with MYC-driven aggressive B-cell lymphomas. Article Tue, 01 Jan 2013 00:00:00 GMT https://ikr.inceif.org/retrieve/2882a9ad-a2b7-4d52-9695-fb01218f2ecd/Hematology-2013-Ott-575-83.pdf.jpg 2013-01-01T00:00:00Z